Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

N. Shore, I. Mincik, M. DeGuenther, V. Student, M. Jievaltas, J. Patockova, K. Simpson, CH. Hu, ST. Huang, Y. Li, Y. Lee, B. Chien, J. Mao,

. 2020 ; 38 (1) : 111-119. [pub] 20190403

Jazyk angličtina Země Německo

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028692

OBJECTIVES: To determine the safety, efficacy and pharmacokinetic (PK) profile of a pre-mixed depot formulation of leuprolide mesylate subcutaneous injectable suspension (LMIS) 50 mg for up to 1 year of treatment for subjects with advanced prostate cancer. PATIENTS AND METHODS: In this open-label, multicenter study, prostate cancer patients with indication for androgen ablation therapy received two subcutaneous injection of LMIS 50 mg 6 months apart and were followed for an additional 6 months. Two efficacy primary end points were the percentage of subjects with a serum testosterone level ≤ 50 ng/dL by Day 28 as well as the percentage of subjects with similar testosterone suppression from Day 28 to Day 336. RESULTS: Of the 137 enrolled subjects, 15 (10.9%) subjects did not complete the study, including 5 subjects who terminated early due to an adverse event. By Day 28, 98.5% (95% confidence interval 94.8-99.8) of the subjects achieved a castrate testosterone level. At the end of the study, 97% and 95.9% of the subjects had serum testosterone level ≤ 50 ng/dL and ≤ 20 ng/dL, respectively. LMIS 50 mg significantly reduced serum prostate-specific antigen levels after its first injection and this PSA declination effect remained until the end of the study. No statistically significant change was observed in worsening bone pain or urinary symptom assessments during the study. Hot flush (48.9%) and hypertension (14.6%) were the two most common adverse events reported. CONCLUSIONS: LMIS 50 mg, administered at 6-month intervals, effectively suppressed serum testosterone level, and demonstrated a consistent safety profile.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028692
003      
CZ-PrNML
005      
20210114154736.0
007      
ta
008      
210105s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00345-019-02741-7 $2 doi
035    __
$a (PubMed)30941562
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Shore, Neal $u Carolina Urologic Research Center, Suite B, 823 82nd Parkway, Myrtle Beach, SC, 29579, USA. nshore@gsuro.com.
245    12
$a A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients / $c N. Shore, I. Mincik, M. DeGuenther, V. Student, M. Jievaltas, J. Patockova, K. Simpson, CH. Hu, ST. Huang, Y. Li, Y. Lee, B. Chien, J. Mao,
520    9_
$a OBJECTIVES: To determine the safety, efficacy and pharmacokinetic (PK) profile of a pre-mixed depot formulation of leuprolide mesylate subcutaneous injectable suspension (LMIS) 50 mg for up to 1 year of treatment for subjects with advanced prostate cancer. PATIENTS AND METHODS: In this open-label, multicenter study, prostate cancer patients with indication for androgen ablation therapy received two subcutaneous injection of LMIS 50 mg 6 months apart and were followed for an additional 6 months. Two efficacy primary end points were the percentage of subjects with a serum testosterone level ≤ 50 ng/dL by Day 28 as well as the percentage of subjects with similar testosterone suppression from Day 28 to Day 336. RESULTS: Of the 137 enrolled subjects, 15 (10.9%) subjects did not complete the study, including 5 subjects who terminated early due to an adverse event. By Day 28, 98.5% (95% confidence interval 94.8-99.8) of the subjects achieved a castrate testosterone level. At the end of the study, 97% and 95.9% of the subjects had serum testosterone level ≤ 50 ng/dL and ≤ 20 ng/dL, respectively. LMIS 50 mg significantly reduced serum prostate-specific antigen levels after its first injection and this PSA declination effect remained until the end of the study. No statistically significant change was observed in worsening bone pain or urinary symptom assessments during the study. Hot flush (48.9%) and hypertension (14.6%) were the two most common adverse events reported. CONCLUSIONS: LMIS 50 mg, administered at 6-month intervals, effectively suppressed serum testosterone level, and demonstrated a consistent safety profile.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a hormonální protinádorové látky $x aplikace a dávkování $7 D018931
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a lidé $7 D006801
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a leuprolid $x aplikace a dávkování $7 D016729
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methansulfonáty $x aplikace a dávkování $7 D008698
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $x metody $7 D009367
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a nádory prostaty $x krev $x diagnóza $x farmakoterapie $7 D011471
650    _2
$a testosteron $x krev $7 D013739
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Mincik, Ivan $u Urocentrum Milab, s.r.o. Hollého 14/D, 080 01, Presov, Slovak Republic.
700    1_
$a DeGuenther, Mark $u Urology Center of Alabama, 3485 Independence Drive, Homewood, AL, 35209, USA.
700    1_
$a Student, Vladimir $u Fakultní Nemocnice Olomouc Urologická Klinika, I. P. Pavlova 6, Olomouc, 779 00, Czech Republic.
700    1_
$a Jievaltas, Mindaugas $u Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Eivenių 2, Kaunas, 50009, Lithuania.
700    1_
$a Patockova, Jitka $u QPS Holdings, LLC, Three Innovation Way, Suite 240, Newark, DE, 19711, USA.
700    1_
$a Simpson, Kelle $u QPS Holdings, LLC, Three Innovation Way, Suite 240, Newark, DE, 19711, USA.
700    1_
$a Hu, Chu-Hsuan $u QPS Holdings, LLC, Three Innovation Way, Suite 240, Newark, DE, 19711, USA.
700    1_
$a Huang, Shih-Tsung $u Department of Surgery and Urology, Chang Gung Memorial Hospital-Linkou, Chung Gung University, College of Medicine, Taoyuan, Taiwan.
700    1_
$a Li, Yuhua $u Foresee Pharmaceuticals Co., Ltd., 3 F, No 19-3, Sanchong Road, NanKang Dist., Taipei, 11501, Taiwan, R.O.C.
700    1_
$a Lee, Yisheng $u Foresee Pharmaceuticals Co., Ltd., 3 F, No 19-3, Sanchong Road, NanKang Dist., Taipei, 11501, Taiwan, R.O.C.
700    1_
$a Chien, Ben $u Foresee Pharmaceuticals Co., Ltd., 3 F, No 19-3, Sanchong Road, NanKang Dist., Taipei, 11501, Taiwan, R.O.C.
700    1_
$a Mao, John $u Foresee Pharmaceuticals Co., Ltd., 3 F, No 19-3, Sanchong Road, NanKang Dist., Taipei, 11501, Taiwan, R.O.C.
773    0_
$w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 38, č. 1 (2020), s. 111-119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30941562 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154732 $b ABA008
999    __
$a ok $b bmc $g 1609027 $s 1119872
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 38 $c 1 $d 111-119 $e 20190403 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace